The baseline evaluation was conducted before the introduction of NUC therapy for hepatitis B, and patients with pronounced liver damage (in total 17) were first treated with pegylated interferon‐alpha (IFN). This evidence concerns the gene IFNA1 and hepatitis B virus infection.